INAB

SEC source: 0001209191-23-058719 · doc4.xml · derivative · entry 2

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,459

Underlying: Common Stock · 102,459 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058719 · doc4.xml · nonDerivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,448

F1 · price: The reported securities are included within 102,459 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock.

SEC source: 0001209191-23-058713 · doc4.xml · derivative · entry 4

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058713 · doc4.xml · derivative · entry 3

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058713 · doc4.xml · nonDerivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,440

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

SEC source: 0001209191-23-058721 · doc4.xml · derivative · entry 3

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,049

Underlying: Common Stock · 2,049 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058721 · doc4.xml · derivative · entry 2

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,049

Underlying: Common Stock · 2,049 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058721 · doc4.xml · nonDerivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,549

F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock.

SEC source: 0001209191-23-058720 · doc4.xml · derivative · entry 3

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058720 · doc4.xml · derivative · entry 2

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058720 · doc4.xml · nonDerivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

SEC source: 0001209191-23-058718 · doc4.xml · derivative · entry 8

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058718 · doc4.xml · derivative · entry 7

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058718 · doc4.xml · nonDerivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,421,512

F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

SEC source: 0001209191-23-058714 · doc4.xml · derivative · entry 3

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,639

Underlying: Common Stock · 1,639 shares

Expires 2028-12-13

F1 · price: The reported securities are included within 1,639 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 1,639 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058714 · doc4.xml · derivative · entry 2

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,639

Underlying: Common Stock · 1,639 shares

Expires 2025-06-13

F1 · price: The reported securities are included within 1,639 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 1,639 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001209191-23-058714 · doc4.xml · nonDerivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,369

F1 · price: The reported securities are included within 1,639 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 1,639 shares of common stock.

SEC source: 0001209191-23-057915 · doc4.xml · derivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,800

Underlying: Common Stock · 54,800 shares

Expires 2033-12-06

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on January 6, 2024, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-049607 · doc4.xml · nonDerivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

SEC source: 0001209191-23-047526 · doc4.xml · nonDerivative · entry 1

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,263

SEC source: 0001209191-23-047525 · doc4.xml · nonDerivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,339,545

SEC source: 0001209191-23-044002 · doc4.xml · nonDerivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: These securities are held by Transcend Partners Opportunity Fund I LLC ("Transcend"). Effective July 28, 2023, Transcend appointed new managing members and adopted a policy pursuant to which voting and dispositive decisions with respect to the Issuer's securities require the approval of at least two of Transcend's managers, Grant Fairbairn, Nina Fairbairn and Scott Kintz. Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by two or more individuals, and a voting and dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity's securities. Based upon the foregoing analysis, neither an individual manager of Transcend nor the Reporting Person exercises voting or dispositive control over any of the Issuer's securities, even those in which such person may hold a pecuniary interest.

F1 · ownership.nature: These securities are held by Transcend Partners Opportunity Fund I LLC ("Transcend"). Effective July 28, 2023, Transcend appointed new managing members and adopted a policy pursuant to which voting and dispositive decisions with respect to the Issuer's securities require the approval of at least two of Transcend's managers, Grant Fairbairn, Nina Fairbairn and Scott Kintz. Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by two or more individuals, and a voting and dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity's securities. Based upon the foregoing analysis, neither an individual manager of Transcend nor the Reporting Person exercises voting or dispositive control over any of the Issuer's securities, even those in which such person may hold a pecuniary interest.

SEC source: 0001209191-23-039509 · doc4.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,150

Underlying: Common Stock · 87,150 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-039508 · doc4.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,800

Underlying: Common Stock · 67,800 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-039510 · doc4.xml · derivative · entry 1

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,000

Underlying: Common Stock · 134,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-039507 · doc4.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,600

Underlying: Common Stock · 77,600 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-039506 · doc4.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,950

Underlying: Common Stock · 393,950 shares

Expires 2033-06-21

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on June 21, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038121 · doc4.xml · derivative · entry 1

Greenwood Luba · CIK 0001853815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038119 · doc4.xml · derivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038124 · doc4.xml · derivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038123 · doc4.xml · derivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038122 · doc4.xml · derivative · entry 1

Whitfill Travis · CIK 0001830178 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-038120 · doc4.xml · derivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-027027 · doc4.xml · derivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2033-05-01

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on June 1, 2023, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-024698 · doc4.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-04-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-024701 · doc4.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-04-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-024692 · doc4.xml · derivative · entry 1

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-04-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-024695 · doc4.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-04-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-024694 · doc4.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,950

Underlying: Common Stock · 393,950 shares

Expires 2028-04-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-039505 · doc4a.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,950

Underlying: Common Stock · 393,950 shares

Expires 2033-04-14

F1 · derivative.exercise_price: The initial Form 4 inadvertently listed the wrong exercise price and expiration date. This amendment reflects the revised exercise price and expiration date for this option.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on April 14, 2024 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F1 · derivative.expiration_date: The initial Form 4 inadvertently listed the wrong exercise price and expiration date. This amendment reflects the revised exercise price and expiration date for this option.

SEC source: 0001104659-22-126432 · tm2232534-1_4seq1.xml · nonDerivative · entry 3

Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner

BIOS Fund II, LP · CIK 0001714576 · Director · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · Director · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · Director · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · Director · 10% owner

BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 570,724

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F7 · ownership.nature: The securities are directly held by Bios Fund III.

SEC source: 0001104659-22-126432 · tm2232534-1_4seq1.xml · nonDerivative · entry 2

Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner

BIOS Fund II, LP · CIK 0001714576 · Director · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · Director · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · Director · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · Director · 10% owner

BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,727,597

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F6 · ownership.nature: The securities are directly held by Bios Fund III QP.

SEC source: 0001104659-22-126432 · tm2232534-1_4seq1.xml · nonDerivative · entry 1

Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner

BIOS Fund II, LP · CIK 0001714576 · Director · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · Director · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · Director · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · Director · 10% owner

BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 601,980

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58, inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F5 · ownership.nature: The securities are directly held by Bios Fund III NT.

SEC source: 0001104659-22-126433 · tm2232534-2_4seq1.xml · nonDerivative · entry 3

Kreis Leslie W. · CIK 0001813316 · Director · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · Director · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner

Cavu Management, LP · CIK 0001813270 · Director · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 570,724

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58 inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F7 · ownership.nature: The securities are directly held by Bios Fund III.

SEC source: 0001104659-22-126433 · tm2232534-2_4seq1.xml · nonDerivative · entry 2

Kreis Leslie W. · CIK 0001813316 · Director · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · Director · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner

Cavu Management, LP · CIK 0001813270 · Director · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,727,597

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58 inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F6 · ownership.nature: The securities are directly held by Bios Fund III QP.

SEC source: 0001104659-22-126433 · tm2232534-2_4seq1.xml · nonDerivative · entry 1

Kreis Leslie W. · CIK 0001813316 · Director · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · Director · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner

Cavu Management, LP · CIK 0001813270 · Director · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 601,980

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.37 to $2.58 inclusive. The reporting persons undertake to provide to IN8BIO, Inc., any security holder of IN8BIO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (12) to this Form 4.

F1 · ownership.nature: Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.

F2 · ownership.nature: Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F3 · ownership.nature: Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.

F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F5 · ownership.nature: The securities are directly held by Bios Fund III NT.

SEC source: 0001209191-22-054513 · doc4.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,796

Underlying: Common Stock · 59,796 shares

Expires 2032-10-21

F1 · derivative.exercise_date: The option will vest in three equal annual installments commencing on October 21, 2024, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-22-054512 · doc4.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,555

Underlying: Common Stock · 60,555 shares

Expires 2032-10-21

F1 · derivative.exercise_date: The option will vest in three equal annual installments commencing on October 21, 2024, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-22-054506 · doc4.xml · derivative · entry 1

Goswami Trishna · CIK 0001894243 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,427

Underlying: Common Stock · 68,427 shares

Expires 2032-10-21

F1 · derivative.exercise_date: The option will vest in three equal annual installments commencing on October 21, 2024, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-22-054509 · doc4.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,826

Underlying: Common Stock · 62,826 shares

Expires 2032-10-21

F1 · derivative.exercise_date: The option will vest in three equal annual installments commencing on October 21, 2024, subject to the Reporting Person continuing to provide service through each such date.